{
    "clinical_study": {
        "@rank": "9962", 
        "arm_group": [
            {
                "arm_group_label": "Standarddose Saxagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Saxagliptin  5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months"
            }, 
            {
                "arm_group_label": "Lifestyle intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "Lifestyle intervention for 6 months"
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Metformin  500 mg (tablet) ,500mg three times  a day  and lifestyle intervention for 6 months"
            }, 
            {
                "arm_group_label": "low dose Saxagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the effect of Saxagliptin in the newly diagnosed\n      people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate DPP 4\n      inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its\n      influences on the targets of obesity related metabolic abnormalities, to explore new ways\n      for intervention on populations with pre-diabetes and obesity ."
        }, 
        "brief_title": "Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity", 
        "condition": "Prediabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Obesity", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "Materials and Methods:                                                        This is a\n      perspectiveness ,randomized, opening study, patients will be randomly assigned to the\n      standarddose Saxagliptin  group ,the lifestyle intervention group,the Metformin group and\n      the low dose Saxagliptin group with a 6-month treatment period.\n\n      Oral glucose tolerance test  will  examined before and 6 months post-treatment during the\n      trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Newly diagnosed insulin resistance or glucose intolerance .\n\n        2.20 to 70 years of age.\n\n        3.BMI\u226528kg/m2\uff0cor BMI\uff1e25kg/m2 beside waistline\u226580cm\uff08female)\uff0c\u226590cm(male).\n\n        Exclusion Criteria:\n\n          1. Under Diabetes Mellitus treatment.\n\n          2. Allergy to dipeptidyl peptidase 4 (DPP-4) inhibitors .\n\n          3. Active heart failure.\n\n          4. Unwilling or unable to sign inform consents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960205", 
            "org_study_id": "ZXL-201308"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standarddose Saxagliptin", 
                "description": "5mg a day for 6 months", 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Onglyza"
            }, 
            {
                "arm_group_label": "low dose Saxagliptin", 
                "description": "2.5 mg a day for 6 months", 
                "intervention_name": "saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Onglyza"
            }, 
            {
                "arm_group_label": "Metformin", 
                "description": "500mg three times a day for 6 months", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug", 
                "other_name": "melbine"
            }, 
            {
                "arm_group_label": "Lifestyle intervention", 
                "description": "lifestyle intervention for 6 months", 
                "intervention_name": "lifestyle intervention", 
                "intervention_type": "Other", 
                "other_name": "living way intervention"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Saxagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Saxagliptin, prediabetes, glucose intolerance,obesity", 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "contact": {
                "email": "zhouxinli0301@163.com", 
                "last_name": "Xinli Zhou, MD, PhD", 
                "phone": "15168889976"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250021"
                }, 
                "name": "Shandong Provincial Hospital"
            }, 
            "investigator": {
                "last_name": "Xinli Zhou, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity", 
        "overall_contact": {
            "email": "zhouxinli0301@163.com", 
            "last_name": "Xinli Zhou, MD,PhD", 
            "phone": "15168889976"
        }, 
        "overall_official": {
            "affiliation": "Shandong Provincial Hospital", 
            "last_name": "Xinli Zhou, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "oral glucose tolerance test", 
            "safety_issue": "No", 
            "time_frame": "Change of Blood sugar from baseline at 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960205"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong Provincial Hospital", 
            "investigator_full_name": "Xinli Zhou\uff0cMD\uff0cPHD", 
            "investigator_title": "Xinli Zhou", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shandong Provincial Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Chinese Medical Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shandong Provincial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}